Abstract
Intravenous immunoglobulin (IVIGs) preparations, which are used in the
treatment of many immune-based diseases, also have an important place in
hematology practice. It is an important treatment option with many
different immunoregulatory roles. There is a limitation of its use on
adult patients due to the lack of retrospective data. In our study, the
retrospective usage indications, responses and rates of IVIG
preparations evaluated in our Hematology Clinic and used in various
indications between January 2010 and January 2020 were attempted to be
put forth. Our targets for treatment responses were as follows: For
immune thrombocytopenia, the platelet count target was 30000 x 103/µL
and above; no hospitalization need for secondary hypogammaglobulinemia;
no replacement need for hemolytic anemia after IVIG and a hemoglobin
level above 8 g/dl. When 166 patients were examined in total, 66 were
diagnosed with immune thrombocytopenic purpura (ITP) (39.8%) . There
were emergency indications for all patients with thrombocytopenia before
getting a primary diagnosis. The number of patients who used IVIG before
getting a primary diagnosis was 79 (47.6%), 41 of whom (51.9%) were
diagnosed with immune thrombocytopenic purpura in follow up. The
expected response was 36.1% with 60 patients within the entire patient
group. With further examination performed after emergency usage, the
diagnoses received by the patients were revealed. The response was
58.5% with 24 patients in whom IVIG was used under emergency conditions
and deep thrombocytopenia before getting a primary diagnosis and were
diagnosed with ITP after further examinations